Literature DB >> 4344027

Immunization of mice against encephalomyocarditis virus. II. Intraperitoneal and respiratory immunization with ultraviolet-inactivated vaccine: effect of Bordetella pertussis extract on the immune response.

W J Bogaerts.   

Abstract

Mice were immunized by intraperitoneal (ip) or respiratory administration of ultraviolet-inactivated virus alone or with Bordetella pertussis extract (BPE) as an adjuvant. The effect of immunization was tested by determination of antibody titers and by survival of a lethal challenge with 200 LD(50) of a virulent (large-plaque variant) strain of EMC virus. For plain vaccine the ip 50% effective dose (ED(50)) was 37 hemagglutination units (HAU; ca. 4 x 10(6) plaque-forming unit equivalents); with adjuvant the ip ED(50) was reduced to 20 HAU. After respiratory immunization by intratracheal injection, an ED(50) value of 100 HAU was found, which was not affected by BPE. After ip vaccination the primary immune response was enhanced by BPE, but the challenge response, measured 3 weeks after challenge, was unaffected. Respiratory immunization induced a primary response which was not influenced by BPE, but here the challenge response was enhanced by the adjuvant. After secondary treatment (challenge or booster vaccination) serum antibodies and protection against challenge persisted for at least 1 year.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4344027      PMCID: PMC422567          DOI: 10.1128/iai.6.4.513-517.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

1.  Immunization of mice against encephalomyocarditis virus. I. Purification, concentration, and inactivation of encephalomyocarditis virus.

Authors:  W J Bogaerts
Journal:  Infect Immun       Date:  1972-10       Impact factor: 3.441

2.  The effect of parenteral and oral immunization on encephalomyocarditis infection in mice.

Authors:  T G Lawrence; H Collins
Journal:  Proc Soc Exp Biol Med       Date:  1970-03

3.  The immunologic response of the mouse to aerosols of an attenuated encephalomyocarditis virus strain.

Authors:  C M Prato; T G Akers
Journal:  J Immunol       Date:  1969-07       Impact factor: 5.422

4.  Peroral infection and resistance to reinfection with encephalomyocarditis virus in the mouse.

Authors:  R Friedman; R M Maenza
Journal:  J Infect Dis       Date:  1968-04       Impact factor: 5.226

5.  Isolation from Bordetella pertussis of protective antigen free from toxic activity and histamine sensitizing factor.

Authors:  J Nagel
Journal:  Nature       Date:  1967-04-01       Impact factor: 49.962

6.  Virulence and immunogenicity in mice of airborne encephalomyocarditis viruses and their infectious nucleic acids.

Authors:  T G Akers; S B Bond; C Papke; W R Leif
Journal:  J Immunol       Date:  1966-09       Impact factor: 5.422

7.  Immunogenicity of purified venezuelan equine encephalitis virus inactivated by ionizing radiation.

Authors:  J Gruber
Journal:  Infect Immun       Date:  1971-04       Impact factor: 3.441

8.  Purification, concentration, and inactivation of Venezuelan equine encephalitis virus.

Authors:  J Gruber
Journal:  Appl Microbiol       Date:  1970-09
  8 in total
  4 in total

1.  Adjuvant enhancement of humoral immune response to chemically inactivated bovine viral diarrhea virus.

Authors:  K S Chen; D W Johnson; C C Muscoplat
Journal:  Can J Comp Med       Date:  1985-01

2.  Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Immunization of mice with live attenuated encephalomyocarditis virus: local immunity and survival.

Authors:  W J Bogaerts
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

4.  Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.